Our antibodies are used in research studies worldwide Keep reading our latest Research Roundup! The following three studies have successfully utilized Atlas Antibodies products in stem cell research.

1) SVCT2 promotes neural stem/progenitor cells migration by activating CDC42 after ischemic stroke 

Ischemic stroke remains a leading cause of death and long-term disability through an irreversible “ischemic cascade,” including disrupted energy balance related to variations in oxygen and glucose concentrations and the depletion of cellular energy stores, and the release of inflammatory mediators. Increasing evidence has demonstrated that activating endogenous neural stem progenitor cells (NSPCs) can pave the way for the augmented long-term experimental recovery of injured brain tissue. 

This study indicates that the sodium-vitamin C cotransporter 2 (SLC23A2 or SVCT2), is mainly expressed in the brain and located in NSPC of the inner and outer subventricular zone, promotes the migration of NPSCs through CDC42 activation to facilitate F-actin assembling, which importantly enlarges the therapeutic scope of ascorbic acid and the role of SVCT2 in NSPCs migration after brain injury. 

The immunofluorescent staining on mouse brain sections was done using Atlas Antibodies’ polyclonal anti-SLC23A2 antibody (HPA052825)  

Yang et al. SVCT2 promotes neural stem/progenitor cells migration through activating CDC42 after ischemic stroke. Front Cell Neurosci, 2019; 13:429.

2) Loss of ZC4H2 and mRNF220  inhibits  neural  stem  cell  proliferation and promotes neuronal differentiation

Changes in the cell-cycle length in neural stem cells (NSCs) affect their cell fate. Prolonged G0/G1-phase promotes neurogenesis and neuronal differentiation through increased expression of pro-neural factors. 

This study uncovers the regulatory role of the proteins ZC4H2 (a Zn-finger protein) and RNF220 (an E3 ubiquitin ligase) in NSCs proliferation and differentiation. Mutations in ZC4H2 can cause clinical arthrogryposis multiplex congenita, intellectual disability, epilepsy, hypotonia, and other ZC4H2-associated rare disorders. 

The main finding of the study is that ZC4H2/ RNF220-complex causes an upregulation of the neuronal cell-lineage protein Cend-1. Hence the authors could show that ZC4H2 and RNF220 are required in neural stem cell proliferation and differentiation through Cend1.  

This study employed Atlas Antibodies’ polyclonal anti-RNF220 antibody (HPA027578) as the primary antibody for a Western blot on harvest and lysed murine NSCs. 

Zhang et al. Loss of ZC4H2 and RNF220 inhibits neural stem cell proliferation and promotes neuronal differentiation. Cells, 2020 Jul 1; 9(7):1600.  

3) Loss of Arid1a promotes neuronal survival following optic nerve injury

Optic nerve trauma and optic neuropathies lead to progressive loss of retinal ganglion cells (RGCs), associated with visual function deficits. Mature, differentiated RGCs cannot regenerate after optic nerve injury, but adult RGCs can regain the ability to support axon regeneration by manipulating reprogramming factors, such as Klf4, c-myc, and Lin28.  

Despite the documented roles of Arid1A in processes related to embryonic development, tissue repair, apoptosis, and tumor formation, it remains unclear whether manipulating ARID1A is sufficient to enable axon regeneration or increase RGC survival following optic nerve injury.  

This study investigated the expression of Arid1A in sensory neurons and RGCs. Additionally, profiling the chromatin accessibility and gene expression profiles in mature RCCs was executed to discover the mechanisms of how Arid1A modulates neuronal survival. 

The study showed Arid1A -deletion reduced the signal at the Socs3 loci associated with a lowered level of Socs3 mRNA. The signaling protein Socs3 is a known promoter of axonal regeneration and RGC survival after optic nerve injury. 

In this study, the Atlas Antibodies polyclonal anti-ARID1A antibody (HPA005456) was used as the primary reagent.   

Peng XQ et al. Loss of Arid1a promotes neuronal survival following optic nerve injury. Front. Cell. Neurosci., 2020; 14:131.